authors Dent, S Verma, Sh Latreille, J Rayson, D Clemons, M Mackey, J Verma, Su Lemieux, J Provencher, L Chia, S Wang, B Pritchard, Kathleen
keywords AKT COMBINATION DISEASE PROGRESSION EXPERIENCE HER-2 HER2-targeted therapy HERCEPTIN-INDUCED INHIBITION Life Sciences & Biomedicine MONOCLONAL-ANTIBODY Metastatic breast cancer Oncology SAFETY SURVIVAL Science & Technology TRASTUZUMAB re-treatment trastuzumab treatment beyond progression